Omrix greenshoe exercised, raising size of IPO to $39.5 million

By Lisa Kerner

Erie, Pa., May 8 - Omrix Biopharmaceuticals, Inc. said the underwriters of its initial public offering have exercised their over-allotment option to purchase an additional 515,625 shares of its common stock priced at $10 per share.

With the greenshoe, the total size of the deal is now 3,953,125 shares or $39.5 million.

The company expects to net about $35 million.

The issue originally priced on April 20.

UBS Investment Bank acted as bookrunner and co-lead manager. CIBC World Markets is acting as co-lead manager, and Leerink Swann & Co. and Oppenheimer & Co. are co-managers.

Omrix is a commercial-stage biopharmaceutical company located in New York City.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.